Trials / Terminated
TerminatedNCT01127178
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7016 + TMZ | Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component. |
Timeline
- Start date
- 2010-03-29
- Primary completion
- 2011-02-24
- Completion
- 2011-02-24
- First posted
- 2010-05-20
- Last updated
- 2024-10-10
- Results posted
- 2024-10-10
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01127178. Inclusion in this directory is not an endorsement.